Editorial Material
Cardiac & Cardiovascular Systems
Bo Liang, Yi Liang, Rui Li, Ning Gu
Summary: Renal denervation is emerging as a promising non-drug treatment for resistant hypertension, but there is still a lack of evaluation on its long-term blood pressure control effect. Further research is needed to address the limitations and compare the antihypertensive effects of different renal denervation systems.
CARDIOVASCULAR DIABETOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Karl Fengler, Paul Reimann, Karl-Philipp Rommel, Karl-Patrik Kresoja, Stephan Blazek, Matthias Unterhuber, Christian Besler, Maximilian von Roeder, Michael Bohm, Steffen Desch, Holger Thiele, Philipp Lurz
Summary: Observational data indicates that blood pressure response to renal sympathetic denervation is associated with improved long-term clinical outcomes. The study found that patients who responded to the treatment had significantly fewer major adverse cardiovascular events during a median follow-up period of 48 months compared to non-responders.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Article
Peripheral Vascular Disease
Byeong-Keuk Kim, Hyo-Soo Kim, Seung-Jung Park, Chang Gyu Park, Ki Bae Seung, Hyeon-Cheol Gwon, Dong-Ju Choi, Tae Hoon Ahn, Chong Jin Kim, Hyuck Moon Kwon, Cheryl Shen, Yangsoo Jang
Summary: The study investigated the long-term safety and efficacy of renal denervation in Korean patients, showing significant reductions in office systolic blood pressure up to 36 months post-procedure with rare adverse events. Patients with and without diabetes mellitus had similar reductions in office systolic blood pressure after renal denervation.
HYPERTENSION RESEARCH
(2021)
Article
Peripheral Vascular Disease
Pariya Panchavinnin, Sirisawat Wanthong, Weranuj Roubsanthisuk, Damras Tresukosol, Peera Buranakitjaroen, Chavalit Chotruangnapa, Wattana Watanapa, Rungtiwa Pongakasira, Nattawut Wongpraparut
Summary: The study aimed to determine the long-term outcome of renal denervation (RDN) in patients with resistant hypertension. Patients were followed up at different time points up to 9 years, and the effectiveness of RDN was observed to be >80% during the entire follow-up period.
HYPERTENSION RESEARCH
(2022)
Article
Medicine, General & Internal
Vytautas Juknevicius, Andrius Berukstis, Renata Jukneviciene, Eugenijus Jasiunas, Pranas Serpytis, Aleksandras Laucevicius
Summary: Renal artery denervation procedure provides sustained antihypertensive effects for up to 48 months with no worsening of arterial stiffness post-operation. However, a higher medication burden post-procedure is associated with increased arterial stiffness after 48 months.
MEDICINA-LITHUANIA
(2021)
Article
Cardiac & Cardiovascular Systems
Fiorenzo Simonetti, Raffaele Piccolo, Giovanni Esposito
Summary: Arterial hypertension is a common condition that increases the risk of adverse cardiovascular events. While non-pharmacological and pharmacological interventions are effective, there is a significant percentage of patients who do not respond or cannot tolerate medications. Renal denervation, despite initial setbacks, has shown to be a beneficial and safe treatment option. Further research is needed to determine the optimal technique and patient selection for this procedure.
EUROPEAN HEART JOURNAL SUPPLEMENTS
(2023)
Article
Cardiac & Cardiovascular Systems
Felix Mahfoud, Horst Sievert, Stefan Bertog, Lucas Lauder, Sebastian Ewen, Jean-Philippe Lengele, Wojciech Wojakowski, Roland Schmieder, Markus van der Giet, Michael A. Weber, David E. Kandzari, Helen Parise, Tim A. Fischell, Atul Pathak, Alexandre Persu
Summary: Catheter-based chemical renal denervation with dehydrated alcohol using the Peregrine Catheter appears to safely reduce blood pressure at a 12-month follow-up. There were no major procedural complications, and changes in blood pressure were observed in both ambulatory and office settings. Further randomized and sham controlled studies are needed to confirm these findings.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS
(2021)
Article
Chemistry, Multidisciplinary
Albert Topf, Vera Paar, Janine Grueninger, Bernhard Wernly, Kristen Kopp, Thomas Weber, Christiana Schernthaner, Moritz Mirna, Sarah X. Gharibeh, Robert Larbig, Rudin Pistulli, Uta C. Hoppe, Michael Lichtenauer, Lukas J. Motloch, Mathias C. Brandt
Summary: Renal sympathetic denervation (RSD) has shown promising results in reducing levels of the biomarker sST-2 after three months in patients with therapy resistant hypertension, suggesting sST-2 involvement in remodeling processes post-RSD. Lower baseline sST-2 levels may serve as a potential predictor for early intervention success of RSD.
APPLIED SCIENCES-BASEL
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Liu Yang, Peng Peng Xu, U. Joseph Schoepf, Christian Tesche, Balakrishnan Pillai, Rock H. Savage, Chun Xiang Tang, Fan Zhou, Hao Dong Wei, Zhong Qiang Luo, Qing Gen Wang, Chang Sheng Zhou, Meng Jie Lu, Guang Ming Lu, Long Jiang Zhang
Summary: Fractional flow reserve and plaque progression assessed by serial coronary CT angiography predicted the risk of future major adverse cardiovascular events (MACE), demonstrating better accuracy compared to traditional assessment markers.
EUROPEAN RADIOLOGY
(2021)
Article
Peripheral Vascular Disease
Kazuomi Kario, Felix Mahfoud, David E. Kandzari, Raymond R. Townsend, Michael A. Weber, Roland E. Schmieder, Konstantinos Tsioufis, Stuart Pocock, Sandeep Brar, Douglas A. Hettrick, Martin Fahy, Michael Boehm
Summary: Elevated morning and nighttime blood pressures are associated with increased risk of cardiovascular events. This study compares the long-term changes in morning and nighttime blood pressures in patients with uncontrolled hypertension. The results demonstrate that patients who received renal denervation (RDN) had significantly lower blood pressures compared to the sham control group.
HYPERTENSION RESEARCH
(2023)
Article
Medicine, General & Internal
Michel Azizi, Manish Saxena, Yale Wang, J. Stephen Jenkins, Chandan Devireddy, Florian Rader, Naomi D. L. Fisher, Roland E. Schmieder, Felix Mahfoud, Jason Lindsey, Kintur Sanghvi, Thomas M. Todoran, John Pacella, John Flack, Joost Daemen, Andrew S. P. Sharp, Philipp Lurz, Michael J. Bloch, Michael A. Weber, Melvin D. Lobo, Jan Basile, Lisa Claude, Helen Reeve-Stoffer, Candace K. McClure, Ajay J. Kirtane
Summary: Two studies showed that ultrasound renal denervation can reduce blood pressure in patients with mild to moderate hypertension and treatment-resistant hypertension. This study aimed to investigate the efficacy and safety of ultrasound renal denervation without the influence of antihypertensive medications. The results of a randomized clinical trial demonstrated that ultrasound renal denervation can significantly reduce daytime ambulatory systolic blood pressure in hypertensive patients at 2 months.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Cardiac & Cardiovascular Systems
Alexander C. Razavi, Nathan Wong, Matthew Budoff, Lydia A. Bazzano, Tanika N. Kelly, Jiang He, Camilo Fernandez, Joao Lima, Joseph F. Polak, Morgana Mongraw-Chaffin, Chris defilippi, Moyses Szklo, Alain G. Bertoni, Roger S. Blumenthal, Michael J. Blaha, Seamus P. Whelton
Summary: This study aimed to identify predictors of healthy arterial aging in individuals with MetS or T2D, and found that an optimal overall cardiovascular profile, including traditional and novel risk factors, and a low MetS severity score were more important in maintaining healthy arterial aging than the ideal value of any individual risk factor. More than 40% of adults with MetS or T2D and baseline CAC=0 had long-term absence of CAC, which was strongly associated with an absence of extracoronary atherosclerosis and a low MetS score.
JACC-CARDIOVASCULAR IMAGING
(2021)
Article
Cardiac & Cardiovascular Systems
Alexander Vogt, Jochen Dutzmann, Michael Nussbaum, Daniel Hoyer, Joern Tongers, Axel Schlitt, Daniel Sedding, Alexander Plehn
Summary: In this study, long-term follow-up was conducted on patients who underwent renal sympathetic denervation therapy using radiofrequency. The results showed that renal sympathetic denervation can lead to long-term blood pressure reduction without negative effects on renal function.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Review
Medicine, General & Internal
Max Wagener, Eamon Dolan, Samer Arnous, Joseph Galvin, Andrew W. Murphy, Ivan Casserly, Joseph Eustace, Stephen O'Connor, Charles Mccreery, James Shand, Catherine Wall, Saijad Matiullah, Faisal Sharif
Summary: This article discusses the evidence base for the efficacy and safety of catheter-based renal denervation in lowering blood pressure, and highlights its potential in addressing hypertension and its adverse consequences.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Peripheral Vascular Disease
Felix Mahfoud, Giuseppe Mancia, Roland E. Schmieder, Luis Ruilope, Krzysztof Narkiewicz, Markus Schlaich, Bryan Williams, Flavio Ribichini, Joachim Weil, Khaled Almerri, Faisal Sharif, Lucas Lauder, Marianne Wanten, Martin Fahy, Michael Boehm
Summary: This study investigated whether the number or type of antihypertensive medications were associated with increased long-term blood pressure reductions and cardiovascular outcomes following radiofrequency renal denervation (RDN) in hypertensive patients. The results showed that radiofrequency RDN reduced blood pressure safely through 36 months, regardless of the number and type of baseline antihypertensive medication classes.
